Stock Scorecard



Stock Summary for CollPlant Biotechnologies Ltd New (CLGN)

Total Score

12 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CLGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CLGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CLGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for CLGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for CLGN

Company Overview

Company Name CollPlant Biotechnologies Ltd New
Country USA
Description CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company is headquartered in Rehovot, Israel.
Sector Name LIFE SCIENCES
Industry Name ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Most Recent Quarter 6/30/2022
Next Earnings Date 11/30/2022

Stock Price History

Last Day Price 5.21
Last Day Volume 28,446
Average Daily Volume 21,667
52-Week High 18.30
52-Week Low 4.27
Last Price to 52 Week Low 22.01 %

Valuation Measures

Trailing PE 475.50
Industry PE 71.63
Sector PE 93.33
5-Year Average PE -334.92
Free Cash Flow Ratio 1.59
Industry Free Cash Flow Ratio 18.33
Sector Free Cash Flow Ratio 37.81
Book Value Per Share Most Recent Quarter 3.56
Price to Book Ratio 1.32
Industry Price to Book Ratio 3.14
Sector Price to Book Ratio 15.40
Price to Sales Ratio Twelve Trailing Months 101.47
Industry Price to Sales Ratio Twelve Trailing Months 9.38
Sector Price to Sales Ratio Twelve Trailing Months 25.28

Share Statistics

Total Shares Outstanding 11,086,500
Market Capitalization 57,760,665
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth 104.10 %
Reported EPS Past Year -0.75
Reported EPS Prior Year -0.01
Net Income Twelve Trailing Months -14,994,000
Net Income Past Year 237,000
Net Income Prior Year -5,774,000
Quarterly Revenue Growth YOY -90.40 %
5-Year Revenue Growth 138.93 %

Balance Sheet

Total Cash Per Share 3.27
Total Cash Most Recent Quarter 36,290,000
Total Cash Past Year 13,148,000
Total Cash Prior Year 3,333,000
Net Cash Position Most Recent Quarter 36,290,000
Net Cash Position Past Year 13,148,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Current Ratio Most Recent Quarter 16.21
Total Stockholder Equity Past Year 45,121,000
Total Stockholder Equity Prior Year 4,477,000
Total Stockholder Equity Most Recent Quarter 39,505,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

MACD -0.42
MACD Signal -0.43
20-Day Bollinger Lower Band 8.99
20-Day Bollinger Middle Band 10.52
20-Day Bollinger Upper Band 12.04
Beta 1.00
RSI 38.65
50-Day SMA 9.14
200-Day SMA 10.10

System

Modified 12/1/2022 4:23:42 AM